Karen Russell Randall, Ph.D. Karen Russell Randall, Ph.D. Associate Professor Pharmacology & Toxicology krandall@msm.edu 404-752-1875 Research Wing 314 GRADUATE:

University of the West Indies

Degree: Doctor of Philosophy in Biochemistry





UNDERGRADUATE:

University of the West Indies

Degree: Bachelor of Science (B.Sc., Hons.) in Biochemistry; Bachelor of Science (B.Sc., Hons.) in Chemistry My research focuses on the cellular and molecular mechanisms that underlie the natriuretic and opioidergic regulation of aqueous humor dynamics in the development and maintenance of ocular hypertension. This is based on the hypothesis that opioid and natriuretic systems play important roles in modulating ocular hydrodynamics and that changes in their activity contribute to ocular hypertension. These changes may eventually lead to symptoms reflecting glaucoma. High pressure in the eye is one of the symptoms of primary open angle glaucoma (POAG), the principal cause of blindness in African Americans and a major cause in other segments of the population. Data from our lab demonstrated the presence of opioid and natriuretic peptide receptors in cells involved in IOP regulation, and support our hypothesis that opioids have a role in the reduction of intraocular pressure. However, little is known about how such regulation is achieved. Our studies strongly suggest that the natriuretic peptide (NP) system is involved in the opioid-induced IOP regulation. Like the opioid system, natriuretic peptides regulate cardiovascular and renal functions through their hypotensive and hemodynamic effects. NPs are involved in fluid volume control and may be influenced by endogenous opioids in their volume-regulatory role in the eye. The long-term objective is to determine how opioids and natriuretic peptides function in the anterior chamber (front of the eye) and to determine their roles in the biology of IOP regulation. In the long term, we expect that our findings will reveal essential molecular targets for future therapeutic interventions for POAG and will result in improved outcomes for glaucoma patients.

View additional publications